Trial Profile
The effect of rivaroxaban for hemodynamics in left atrium and thrombotic / thrombolytic biomarkers
Status:
Not yet recruiting
Phase of Trial:
Phase IV
Latest Information Update: 30 May 2016
Price :
$35
*
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Thrombosis
- Focus Pharmacodynamics
- 30 May 2016 New trial record